455280-00-9

Basic information

• Product Name: 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE
• Synonyms: 5-BROMO-1,2-BENZISOXAZOL-3-YLAMINE;5-broMo-1,2-benzoxazol-3-aMine;3-AMino-5-broMobenzo[d]isoxazole
• CAS NO: 455280-00-9
• Molecular Formula: C₇H₅BrN₂O
• Molecular Weight: 213.04
• Mol File: 455280-00-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 371.1°C at 760 mmHg
• Flash Point: 178.2°C
• Appearance: /
• Density: 1.804g/cm³
• Vapor Pressure: 1.06E-05mmHg at 25°C
• Refractive Index: 1.715
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE(455280-00-9)
• EPA Substance Registry System: 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE(455280-00-9)

Safety Data

• Hazardous Substances Data: 455280-00-9(Hazardous Substances Data)

Usage

General Description

5-Bromobenzo[d]isoxazol-3-ylamine is a chemical compound with the molecular formula C7H5BrN2O, which is commonly used as a building block in pharmaceutical and agrochemical research. It is a derivative of benzo[d]isoxazole with a bromine substitution at the 5th position. 5-BROMOBENZO[D]ISOXAZOL-3-YLAMINE is known for its potential in drug discovery and development, particularly in the field of medicinal chemistry. Its structure and properties make it a valuable tool for creating novel compounds with potential therapeutic or agricultural applications. Ongoing research and development in this area continue to uncover the potential of 5-bromobenzo[d]isoxazol-3-ylamine as a versatile and important chemical building block.

InChI:InChI=1/C7H5BrN2O/c8-4-1-2-6-5(3-4)7(9)10-11-6/h1-3H,(H2,9,10)

Upstream product

• 546-88-3 acetylhydroxamic acid 
• 179897-89-3 5-Bromo-2-fluoro-benzonitrile 

Downstream Products

• 1432913-81-9 4-(2-(3-aminobenzo[d]isoxazol-5-yl)-4-chlorophenoxy)-2,5-difluoro-N-(pyrimidin-2-yl)benzenesulfonamide 
• 1432913-82-0 di-tert-butyl (5-(2-(4-(N-benzyl-N-(pyrimidin-2-yl)sulfamoyl)-2,5-difluorophenoxy)-5-chlorophenyl)benzo[d]isoxazol-3-yl)imidodicarbonate 
• 1432913-52-4 4-(2-(3-aminobenzo[d]isoxazol-5-yl)-4-fluorophenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432914-18-5 4-((3-(3-aminobenzo[d]isoxazol-5-yl)pyridin-2-yl)oxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432913-72-8 4-(3-(3-aminobenzo[d]isoxazol-5-yl)-2-oxopyridin-1(2H)-yl)-N-(2,4-dimethoxybenzyl)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432913-73-9 4-((3-(3-aminobenzo[d]isoxazol-5-yl)pyridin-2-yl)oxy)-N-(2,4-dimethoxybenzyl)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432914-10-7 4-(2-(3-aminobenzo[d]isoxazol-5-yl)-4-fluorophenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432914-11-8 di-tert-butyl [5-(5-fluoro-2-hydroxyphenyl)-1,2-benzoxazol-3-yl]imidodicarbonate 
• 1432913-68-2 4-(2-(3-aminobenzo[d]isoxazol-5-yl)phenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432913-95-5 4-(4-chloro-2-(3-(methylamino)benzo[d]isoxazol-5-yl)phenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 
• 1432913-96-6 tert-butyl (5-(5-chloro-2-(4-(N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)sulfamoyl)-2,5-difluorophenoxy)-phenyl)-benzo[d]isoxazol-3-yl)(methyl)carbamate 
• 1432913-93-3 tert-butyl (5-(5-chloro-2-(4-(N-(2,4-dimethoxybenzyl)-N-(1,2,4-thiadiazol-5-yl)sulfamoyl)-2,5-difluorophenoxy)phenyl)benzo[d]isoxazol-3-yl)carbamate 
• 1432913-94-4 tert-butyl (5-(5-chloro-2-hydroxyphenyl)benzo[d]isoxazol-3-yl)carbamate 
• 1432913-44-4 4-(2-(3-aminobenzo[d]isoxazol-5-yl)-4-chlorophenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide 

Relevant articles and documents

COMPOUNDS

A compound of formula (I), or a pharmaceutical salt thereof.

Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models

We report on a novel series of aryl sulfonamides that act as nanomolar potent, isoform-selective inhibitors of the human sodium channel hNaV1.7. The optimization of these inhibitors is described. We aimed to improve potency against hNaV1.7 while minimizing off-target safety concerns and generated compound 3. This agent displayed significant analgesic effects in rodent models of acute and inflammatory pain and demonstrated that binding to the voltage sensor domain 4 site of NaV1.7 leads to an analgesic effect in vivo. Our findings corroborate the importance of hNaV1.7 as a drug target for the treatment of pain.

COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.